101 related articles for article (PubMed ID: 29661497)
1. Postoperative chemotherapy for node-positive cervical cancer: Results of a multicenter phase II trial (JGOG1067).
Matoda M; Takeshima N; Michimae H; Iwata T; Yokota H; Torii Y; Yamamoto Y; Takehara K; Nishio S; Takano H; Mizuno M; Takahashi Y; Takei Y; Hasegawa T; Mikami M; Enomoto T; Aoki D; Sugiyama T
Gynecol Oncol; 2018 Jun; 149(3):513-519. PubMed ID: 29661497
[TBL] [Abstract][Full Text] [Related]
2. Neoadjuvant chemotherapy followed by radical hysterectomy plus postoperative chemotherapy but no radiotherapy for Stage IB2-IIB cervical cancer--irinotecan and platinum chemotherapy.
Matsumura M; Takeshima N; Ota T; Omatsu K; Sakamoto K; Kawamata Y; Umayahara K; Tanaka H; Akiyama F; Takizawa K
Gynecol Oncol; 2010 Nov; 119(2):212-6. PubMed ID: 20709382
[TBL] [Abstract][Full Text] [Related]
3. Phase II study of neoadjuvant chemotherapy with irinotecan hydrochloride and nedaplatin followed by radical hysterectomy for bulky stage Ib2 to IIb, cervical squamous cell carcinoma: Japanese Gynecologic Oncology Group study (JGOG 1065).
Yamaguchi S; Nishimura R; Yaegashi N; Kiguchi K; Sugiyama T; Kita T; Kubushiro K; Kokawa K; Hiura M; Mizutani K; Yamamoto K; Takizawa K
Oncol Rep; 2012 Aug; 28(2):487-93. PubMed ID: 22614251
[TBL] [Abstract][Full Text] [Related]
4. Phase II study of adjuvant chemotherapy with paclitaxel and nedaplatin for uterine cervical cancer with lymph node metastasis.
Takekuma M; Shimokawa M; Nishio S; Omi H; Tabata T; Takei Y; Nasu K; Takahashi Y; Toyota S; Ichikawa Y; Arakawa A; Ito F; Tsubamoto H; Mori T; Hirashima Y; Ito K
Cancer Sci; 2018 May; 109(5):1602-1608. PubMed ID: 29575254
[TBL] [Abstract][Full Text] [Related]
5. Clinical efficacy of neoadjuvant chemotherapy with irinotecan (CPT-11) and nedaplatin followed by radical hysterectomy for locally advanced cervical cancer.
Abou-Taleb HA; Koshiyama M; Matsumura N; Baba T; Yamaguchi K; Hamanishi J; Abiko K; Yamanoi K; Murakami R; Horikawa N; Taha AA; Kitamura S; Konishi I
J Int Med Res; 2016 Apr; 44(2):346-56. PubMed ID: 26831404
[TBL] [Abstract][Full Text] [Related]
6. Postoperative adjuvant concurrent chemoradiotherapy improves survival rates for high-risk, early stage cervical cancer patients.
Ryu HS; Chun M; Chang KH; Chang HJ; Lee JP
Gynecol Oncol; 2005 Feb; 96(2):490-5. PubMed ID: 15661240
[TBL] [Abstract][Full Text] [Related]
7. Neoadjuvant chemotherapy with vincristine and cisplatin followed by radical hysterectomy and pelvic lymphadenectomy for FIGO stage IB bulky cervical cancer: a Gynecologic Oncology Group pilot study.
Eddy GL; Manetta A; Alvarez RD; Williams L; Creasman WT
Gynecol Oncol; 1995 Jun; 57(3):412-6. PubMed ID: 7774847
[TBL] [Abstract][Full Text] [Related]
8. Phase II clinical study of neoadjuvant chemotherapy with CDDP/CPT-11 regimen in combination with radical hysterectomy for cervical cancer with a bulky mass.
Shoji T; Takatori E; Furutake Y; Takada A; Nagasawa T; Omi H; Kagabu M; Honda T; Miura F; Takeuchi S; Kumagai S; Yoshizaki A; Sato A; Sugiyama T
Int J Clin Oncol; 2016 Dec; 21(6):1120-1127. PubMed ID: 27342833
[TBL] [Abstract][Full Text] [Related]
9. Combination of irinotecan (CPT-11) and nedaplatin (NDP) for recurrent patients with uterine cervical cancer.
Ohara T; Kobayashi Y; Yoshida A; Yoshioka N; Yahagi N; Kondo H; Tozawa A; Kiguchi K; Suzuki N
Int J Clin Oncol; 2013 Dec; 18(6):1102-6. PubMed ID: 23095879
[TBL] [Abstract][Full Text] [Related]
10. Clinical effects of irinotecan hydrochloride in combination with cisplatin as neoadjuvant chemotherapy in locally advanced cervical cancer.
Xiong Y; Liang LZ; Cao LP; Min Z; Liu JH
Gynecol Oncol; 2011 Oct; 123(1):99-104. PubMed ID: 21741694
[TBL] [Abstract][Full Text] [Related]
11. Phase I study of combination chemotherapy using irinotecan hydrochloride and nedaplatin for advanced or recurrent cervical cancer.
Machida S; Ohwada M; Fujiwara H; Konno R; Takano M; Kita T; Kikuchi Y; Komiyama S; Mikami M; Suzuki M
Oncology; 2003; 65(2):102-7. PubMed ID: 12931014
[TBL] [Abstract][Full Text] [Related]
12. [Results of different postoperative adjuvant therapies for stage Ib-IIa cervical carcinoma with risk factors].
Wen HW; Huang WP; Liu TY; Ma K; Tao X; Zhu LR; Liao QP
Zhonghua Fu Chan Ke Za Zhi; 2013 Dec; 48(12):920-4. PubMed ID: 24495686
[TBL] [Abstract][Full Text] [Related]
13. Treatment results of adjuvant chemotherapy after radical hysterectomy for intermediate- and high-risk stage IB-IIA cervical cancer.
Takeshima N; Umayahara K; Fujiwara K; Hirai Y; Takizawa K; Hasumi K
Gynecol Oncol; 2006 Nov; 103(2):618-22. PubMed ID: 16777200
[TBL] [Abstract][Full Text] [Related]
14. Radical hysterectomy and pelvic lymphadenectomy for stage IB2 cervical cancer.
Havrilesky LJ; Leath CA; Huh W; Calingaert B; Bentley RC; Soper JT; Alvarez Secord A
Gynecol Oncol; 2004 May; 93(2):429-34. PubMed ID: 15099957
[TBL] [Abstract][Full Text] [Related]
15. Implications of a failed prospective trial of adjuvant therapy after radical hysterectomy for stage Ib-IIa cervical carcinoma with pelvic node metastases.
Lai CH; Tang SG; Chang TC; Tseng CJ; Chou HH; Huang KG; Hsueh S; Hong JH; Huang SL; Lin JD; Soong YK
Changgeng Yi Xue Za Zhi; 1998 Sep; 21(3):291-9. PubMed ID: 9849010
[TBL] [Abstract][Full Text] [Related]
16. Cycles of cisplatin and etoposide affect treatment outcomes in patients with FIGO stage I-II small cell neuroendocrine carcinoma of the cervix.
Pei X; Xiang L; Ye S; He T; Cheng Y; Yang W; Wu X; Yang H
Gynecol Oncol; 2017 Dec; 147(3):589-596. PubMed ID: 28954697
[TBL] [Abstract][Full Text] [Related]
17. Type II radical hysterectomy and adjuvant therapy for pelvic lymph node metastasis with stage IB-IIB cervical carcinoma: a retrospective study of 288 patients.
Zheng M; Huang L; Liu JH; Xiong Y; Li JD; Huang X; He L; Ren YF; Wang HY
J Surg Oncol; 2011 Oct; 104(5):480-5. PubMed ID: 21538358
[TBL] [Abstract][Full Text] [Related]
18. Oncologic outcomes of adjuvant chemotherapy alone after radical surgery for stage IB-IIA cervical cancer patients.
Lee KB; Kim YS; Lee JM
J Gynecol Oncol; 2018 Jan; 29(1):e5. PubMed ID: 29185263
[TBL] [Abstract][Full Text] [Related]
19. The toxicity and long-term efficacy of nedaplatin and paclitaxel treatment as neoadjuvant chemotherapy for locally advanced cervical cancer.
Yin M; Zhang H; Li H; Li X; Liu Y; Chen X; Lou G; Li K
J Surg Oncol; 2012 Feb; 105(2):206-11. PubMed ID: 21815150
[TBL] [Abstract][Full Text] [Related]
20. Randomized phase III trial of sequential adjuvant chemoradiotherapy with or without erythropoietin Alfa in patients with high-risk cervical cancer: results of the NOGGO-AGO intergroup study.
Blohmer JU; Paepke S; Sehouli J; Boehmer D; Kolben M; Würschmidt F; Petry KU; Kimmig R; Elling D; Thomssen C; von Minckwitz G; Möbus V; Hinke A; Kümmel S; Budach V; Lichtenegger W; Schmid P
J Clin Oncol; 2011 Oct; 29(28):3791-7. PubMed ID: 21860000
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
